Clinical protection against caprine herpesvirus 1 genital infection by intranasal administration of a live attenuated glycoprotein E negative bovine herpesvirus 1 vaccine.

Clinical protection against caprine herpesvirus 1 genital infection by intranasal administration of a live attenuated glycoprotein E negative bovine herpesvirus 1 vaccine. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Clinical protection against caprine herpesvirus 1 genital infection by intranasal administration of a live attenuated glycoprotein E negative bovine herpesvirus 1 vaccine. Abstract Text:

Julien Thiry,Maria Tempesta,Michele Camero,Elvira Tarsitano,Benoît Muylkens,François Meurens,Etienne Thiry,Canio Buonavoglia,Julien Thiry,Maria Tempesta,Michele Camero,Elvira Tarsitano,Benoît Muylkens,François Meurens,Etienne Thiry,Canio Buonavoglia,Julien Thiry,Maria Tempesta,Michele Camero,Elvira Tarsitano,Benoît Muylkens,François Meurens,Etienne Thiry,Canio Buonavoglia,

ABSTRACT: BACKGROUND: Caprine herpesvirus 1 (CpHV-1) is responsible of systemic diseases in kids and genital diseases leading to abortions in goats. CpHV-1 is widespread and especially in Mediterranean countries as Greece, Italy and Spain. CpHV-1 is antigenically and genetically closely related to bovine herpesvirus 1 (BoHV-1). Taking into account the biological properties shared by these two viruses, we decided in the current study to assess the protection of a live attenuated glycoprotein E (gE) negative BoHV-1 vaccine against a genital CpHV-1 infection in goats. RESULTS: The vaccine was inoculated intranasally twice three weeks apart followed by a subsequent CpHV-1 intravaginal challenge which is the natural route of infection in three goats. To analyse the safety and the efficacy of this marker vaccine, two groups of three goats served as controls: one immunised with a virulent CpHV-1 and one uninoculated until the challenge. Goats were clinically monitored and all sampling procedures were carried out in a blind manner. The vaccine did not induce any undesirable local or systemic reaction and goats did not excrete gE-negative BoHV-1. After challenge, a significant reduction in disease severity was observed in immunised goats. Moreover, goats immunised with either gE-negative BoHV-1 or CpHV-1 exhibited a significant reduction in the length and the peak of viral excretion. Antibodies neutralising both BoHV-1 and CpHV-1 were raised in immunised goats. CONCLUSION: Intranasal application of a live attenuated gE-negative BoHV-1 vaccine is able to afford a clinical protection and a reduction of virus excretion in goats challenged by a CpHV-1 genital infection.

Clinical protection against caprine herpesvirus 1 genital infection by intranasal administration of a live attenuated glycoprotein E negative bovine herpesvirus 1 vaccine. Publishing Authors By Initials

J Thiry,M Tempesta,M Camero,E Tarsitano,B Muylkens,F Meurens,E Thiry,C Buonavoglia,J Thiry,M Tempesta,M Camero,E Tarsitano,B Muylkens,F Meurens,E Thiry,C Buonavoglia,J Thiry,M Tempesta,M Camero,E Tarsitano,B Muylkens,F Meurens,E Thiry,C Buonavoglia,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Clinical protection against caprine herpesvirus 1 genital infection by intranasal administration of a live attenuated glycoprotein E negative bovine herpesvirus 1 vaccine. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: BMC veterinary research

VOLUME: 3

Page Numbers: 33

Journal Abbreviation: BMC Vet. Res.

ISSN: 1746-6148

DAY: 5

MONTH: 12

YEAR: 2007

Clinical protection against caprine herpesvirus 1 genital infection by intranasal administration of a live attenuated glycoprotein E negative bovine herpesvirus 1 vaccine. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101249759

Clinical protection against caprine herpesvirus 1 genital infection by intranasal administration of a live attenuated glycoprotein E negative bovine herpesvirus 1 vaccine. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Clinical protection against caprine herpesvirus 1 genital infection by intranasal administration of a live attenuated glycoprotein E negative bovine herpesvirus 1 vaccine. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Clinical protection against caprine herpesvirus 1 genital infection by intranasal administration of a live attenuated glycoprotein E negative bovine herpesvirus 1 vaccine.

AFFILIATION: Department of Infectious and Parasitic Diseases, Virology and Viral Diseases, Faculty of Veterinary Medicine, University of Liège, 4000 Liège, Belgium. etienne.thiry@ulg.ac.be.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: BMC Vet Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Clinical protection against caprine herpesvirus 1 genital infection by intranasal administration of a live attenuated glycoprotein E negative bovine herpesvirus 1 vaccine Related Publications

• A real-time PCR assay for detection and quantification of Mycoplasma agalactiae DNA.
• A study on the long-term immunity induced by La Sota strain of Newcastle disease virus grown in a BS/BEK cell line of bovine embryo kidney origin.
• Biological and genetic analysis of a bovine-like coronavirus isolated from water buffalo (Bubalus bubalis) calves.
• Canine adenoviruses and herpesvirus.
• Canine distemper virus.
• Caprine herpesvirus 1 vaccine with the LTK63 mutant as a mucosal adjuvant induces strong protection against genital infection in goats.
• Clinical protection against caprine herpesvirus 1 genital infection by intranasal administration of a live attenuated glycoprotein E negative bovine herpesvirus 1 vaccine.
• Comparison of methods for the detection of methicillin resistance in Staphylococcus aureus isolates from food products.
• Detection and molecular characterization of a canine norovirus.
• Detection and quantification of Anaplasma marginale DNA in blood samples of cattle by real-time PCR.
• Detection of a porcine-like rotavirus in a child with enteritis in Italy.
• Detection of bovine coronavirus using a TaqMan-based real-time RT-PCR assay.
• Detection of infectious canine parvovirus type 2 by mRNA real-time RT-PCR.
• Duplex real-time polymerase chain reaction for simultaneous detection and quantification of Anaplasma marginale and Anaplasma centrale.
• Epizootic abortion related to infections by Chlamydophila abortus and Chlamydophila pecorum in water buffalo (Bubalus bubalis).
• Evaluation of the Antigenic Relationships among Canine Parvovirus Type 2 Variants.
• Evidence for immunisation failure in vaccinated adult dogs infected with canine parvovirus type 2c.
• Experimental infection of dogs with a novel strain of canine coronavirus causing systemic disease and lymphopenia.
• Genetic analysis of feline panleukopenia viruses from cats with gastroenteritis.
• Genetic heterogeneity in the VP7 of group C rotaviruses.
• Genetic heterogeneity of porcine enteric caliciviruses identified from diarrhoeic piglets.
• Identification of a porcine calicivirus related genetically to human sapoviruses.
• Norovirus in captive lion cub (Panthera leo).
• Potent inhibition of genital herpesvirus infection in goats by cidofovir.
• Respiratory disease associated with bovine coronavirus infection in cattle herds in Southern Italy.
• Severe outbreak of bovine coronavirus infection in dairy cattle during the warmer season.
• Specific identification of feline panleukopenia virus and its rapid differentiation from canine parvoviruses using minor groove binder probes.
• The study molecular epidemiology of canine parvovirus, Europe.
• Typing by polymerase chain reaction of buffalo rotaviruses isolated in Italy.
• Use of real-time RT-PCR as a rapid molecular approach for differentiation of field and vaccine strains of bluetongue virus serotypes 2 and 9.